Invention Grant
US08383796B2 Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)
有权
编码程序性死亡配体1（PD-L1）的单克隆抗体的核酸
- Patent Title: Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)
- Patent Title (中): 编码程序性死亡配体1（PD-L1）的单克隆抗体的核酸
-
Application No.: US13091936Application Date: 2011-04-21
-
Publication No.: US08383796B2Publication Date: 2013-02-26
- Inventor: Alan J. Korman , Mark J. Selby , Changyu Wang , Mohan Srinivasan , David B. Passmore , Haichun Huang , Haibin Chen
- Applicant: Alan J. Korman , Mark J. Selby , Changyu Wang , Mohan Srinivasan , David B. Passmore , Haichun Huang , Haibin Chen
- Applicant Address: US NJ Princeton
- Assignee: Medarex, Inc.
- Current Assignee: Medarex, Inc.
- Current Assignee Address: US NJ Princeton
- Agency: Baker Botts LLP
- Main IPC: C07H21/04
- IPC: C07H21/04
Abstract:
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Public/Granted literature
- US20110209230A1 Human Monoclonal Antibodies To Programmed Death Ligand 1 (PD-L1) Public/Granted day:2011-08-25
Information query
